After two years of Covid ruling our lives, it seems like we can finally see the light at the end of the tunnel. That might not be the case if it weren’t for psychedelics. Keep reading to discover how LSD lead to the invention of a tool that’s been essential for detecting Covid!
Here’s what’s in store for you in today’s issue:
🍄 What a DMT trip actually feels like
🍄 The legal psychedelic that’s replacing alcohol
🍄 World’s first DMT trial for depression
🍄 How psychedelics could treat eye disease 👀
🍄 And more.
On this episode of the Daily Mushroom Podcast, we have Michael Kydd, an independent consultant helping psychedelic companies navigate the complex world of government relations. in this emotional episode, Michael talks about his experience with the passing of his mother, and how he believes psychedelics could have strongly benefited his mothers and his family in that difficult time.
Small Pharma (DMT) successfully completed a phase I trial on the safety of DMT in preparation for a phase II trial on depression. Researchers discovered that:
Phase II results are expected in the first half of this year, which will reveal how one dose compares to two doses in treating depression.
Despite having a supportive family and a healthy lifestyle, Sarah had crippling self doubt and suicidal ideation. It wasn’t until she tried ketamine therapy that she realized why she felt these emotions.
The experience revealed that she never healed the scars of feeling unloved during her parents’ divorce. Her dream-like visions on ketamine showed her that separation is a natural part of life, and that she doesn’t need to be perfect to deserve love.
Sarah finally believes “I’m worth being here,’ she says.
Glaucoma can cause irreversible vision loss and blindness. Current medications require multiple daily applications and have side effects like redness and stinging of the eyes.
PharmaDrug (PHRX) wants to develop a superior treatment using analogues of DMT.
The company discovered that the compounds can “activate protective pathways within critical cellular compartments of the eye” to reduce pressure inside the eye.
PharmaDrug will collaborate with the Terasaki Institute for Biomedical Innovation (TIBI) to produce a device that can deliver low doses of the drug to the front of the eye.
Researchers interviewed 36 people immediately after a DMT trip. Here’s what they discovered:
DMT increases theta brain waves, which are associated with dreaming, but it’s unclear why people have such similar “dreams” 🤔
LSD led to the invention of a technology that has slowed the spread of Covid and even earned a Nobel Prize – the PCR test.
Chemist Kary Mullis experimented with lots of synthetic psychedelics, which is no surprise considering he was friends with Albert Hofmann, the creator of LSD.
He believes psychedelics made him think more creatively and gave him visions of sitting on DNA molecules. When asked if he would have invented PCR technology without LSD, he responded, “I doubt it. I seriously doubt it.”
So this pandemic would likely be a lot longer if it weren’t for LSD!
Psychedelic Water is a mildly psychoactive drink made with kava root, a herb used by Pacific Islanders in ceremonies for relaxation. The mood-boosting effect makes it the ideal replacement for alcohol.
Psychedelic Water is having a buy one get one free sale to celebrate the launch of a new flavour – Prickly Pear!
Even multi-platinum producer Murda Beatz is a fan. “I want something that will make me feel good & expand my creativity; Psychedelic Water does exactly that,” he says.
COMPASS Pathways (CMPS) reported 2021 financial result including a net loss of $71.7 million ($1.79 loss per share) and $273.2M in cash. The company had a $60.3M loss ($3.55 loss per share) and $190.3M in cash in 2020.
Filament Health (FH) will license its natural psilocybin to ATMA Journey Centers for use in clinical trials, including an upcoming phase I trial on healthy subjects, which has already received Health Canada approval.
Our friends at TheraPsil helped 86 clinicians apply for Section 56 exemptions so they could participate in a psilocybin therapy training program.
Unfortunately, Health Canada denied the clinicians access to psilocybin, which will impact over 1500 patients who are desperately awaiting psilocybin treatments. Many Canadians will die before they have the chance to try psilocybin therapy.
TheraPsil needs our help to raise $100K to take the Canadian government to court to achieve lasting policy change so that Canadians can access the treatment before it’s too late.